The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Novel Inhibitors of DNA Gyrase: 3D Structure Based Biased Needle Screening, Hit Validation by Biophysical Methods, and 3D Guided Optimization. A Promising Alternative to Random Screening
Abstract
Random screening provided no suitable lead structures in a search for novel inhibitors of the bacterial enzyme DNA gyrase. Therefore, an alternative approach had to be developed. Relying on the detailed 3D structural information of the targeted ATP binding site, our approach combines as key techniques (1) an in silico screening for potential low molecular weight inhibitors, (2) a biased high throughput DNA gyrase screen, (3) validation of the screening hits by biophysical methods, and (4) a 3D guided optimization process. When the in silico screening was performed, the initial data set containing 350 000 compounds could be reduced to 3000 molecules. Testing these 3000 selected compounds in the DNA gyrase assay provided 150 hits clustered in 14 classes. Seven classes could be validated as true, novel DNA gyrase inhibitors that act by binding to the ATP binding site located on subunit B: phenols, 2-amino-triazines, 4-amino-pyrimidines, 2-amino-pyrimidines, pyrrolopyrimidines, indazoles, and 2-hydroxymethyl-indoles. The 3D guided optimization provided highly potent DNA gyrase inhibitors, e. g., the 3,4-disubstituted indazole 23 being a 10 times more potent DNA gyrase inhibitor than novobiocin (3).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NMRPipe: A multidimensional spectral processing system based on UNIX pipes
Delaglio, F., Grzesiek, S., Vuister, G., Zhu, G., Pfeifer, J., & Bax, A. (1995) · Journal of Biomolecular NMR · doi:10.1007/bf00197809 · Cited by 15,965
Discovering High-Affinity Ligands for Proteins: SAR by NMR
Shuker, S. B., Hajduk, P. J., Meadows, R. P., & Fesik, S. W. (1996) · Science · doi:10.1126/science.274.5292.1531 · Cited by 2,041
The program XEASY for computer-supported NMR spectral analysis of biological macromolecules
Bartels, C., Xia, T.-H., Billeter, M., G�ntert, P., & W�thrich, K. (1995) · Journal of Biomolecular NMR · doi:10.1007/bf00417486 · Cited by 1,632
Johnsson, B., Löfås, S., & Lindquist, G. (1991) · Analytical Biochemistry · doi:10.1016/0003-2697(91)90424-r · Cited by 1,262
Karlsson, R., Michaelsson, A., & Mattsson, L. (1991) · Journal of Immunological Methods · doi:10.1016/0022-1759(91)90331-9 · Cited by 1,077
The computer program LUDI: A new method for the de novo design of enzyme inhibitors
B�hm, H.-J. (1992) · Journal of Computer-Aided Molecular Design · doi:10.1007/bf00124387 · Cited by 835
Methicillin-ResistantStaphylococcus aureus in Europe
Voss, A., Milatovic, D., Wallrauch-Schwarz, C., Rosdahl, V. T., & Braveny, I. (1994) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/bf02026127 · Cited by 801
DNA Gyrase: Structure and Function
Reece, R. J., & Maxwell, A. (1991) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409239109114072 · Cited by 728
MAB, a generally applicable molecular force field for structure modelling in medicinal chemistry
Gerber, P. R., & M�ller, K. (1995) · Journal of Computer-Aided Molecular Design · doi:10.1007/bf00124456 · Cited by 593
Crystal structure of an N-terminal fragment of the DNA gyrase B protein
Wigley, D. B., Davies, G. J., Dodson, E. J., Maxwell, A., & Dodson, G. (1991) · Nature · doi:10.1038/351624a0 · Cited by 533
Cited by
Molecular Docking: A Powerful Approach for Structure-Based Drug Discovery
Meng, X.-Y., Zhang, H.-X., Mezei, M., & Cui, M. (2011) · Current Computer Aided-Drug Design · doi:10.2174/157340911795677602 · Cited by 3,771
Improved protein–ligand docking using GOLD
Verdonk, M. L., Cole, J. C., Hartshorn, M. J., Murray, C. W., & Taylor, R. D. (2003) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.10465 · Cited by 3,067
SwissDock, a protein-small molecule docking web service based on EADock DSS
Grosdidier, A., Zoete, V., & Michielin, O. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr366 · Cited by 1,950
A Medicinal Chemist’s Guide to Molecular Interactions
Bissantz, C., Kuhn, B., & Stahl, M. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100112j · Cited by 1,731
Small-molecule inhibitors of protein–protein interactions: progressing towards the dream
Arkin, M. R., & Wells, J. A. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1343 · Cited by 1,705
The Many Roles of Computation in Drug Discovery
Jorgensen, W. L. (2004) · Science · doi:10.1126/science.1096361 · Cited by 1,554
A Common Mechanism Underlying Promiscuous Inhibitors from Virtual and High-Throughput Screening
McGovern, S. L., Caselli, E., Grigorieff, N., & Shoichet, B. K. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm010533y · Cited by 1,042
Optical biosensors in drug discovery
Cooper, M. A. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd838 · Cited by 1,015
Rees, D. C., Congreve, Murray, C. W., & Carr, R. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1467 · Cited by 798
Combining docking and molecular dynamic simulations in drug design
Alonso, H., Bliznyuk, A. A., & Gready, J. E. (2006) · Medicinal Research Reviews · doi:10.1002/med.20067 · Cited by 759
Computer-aided drug discovery and development (CADDD): in silico-chemico-biological approach
Kapetanovic, I. M. (2008) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2006.12.006 · Cited by 662
Structure-based virtual screening: an overview
Lyne, P. D. (2002) · Drug Discovery Today · doi:10.1016/s1359-6446(02)02483-2 · Cited by 662
Erlanson, D. A., McDowell, R. S., & O'Brien, T. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm040031v · Cited by 642
A Specific Mechanism of Nonspecific Inhibition
McGovern, S. L., Helfand, B. T., Feng, B., & Shoichet, B. K. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm030266r · Cited by 598
Molecular Docking: Challenges, Advances and its Use in Drug Discovery Perspective
Saikia, S., & Bordoloi, M. (2019) · Current Drug Targets · doi:10.2174/1389450119666181022153016 · Cited by 571
Survey of the year 2003 commercial optical biosensor literature
Rich, R. L., & Myszka, D. G. (2005) · Journal of Molecular Recognition · doi:10.1002/jmr.726 · Cited by 505
Lead discovery using molecular docking
Shoichet, B. K., McGovern, S. L., Wei, B., & Irwin, J. J. (2002) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(02)00339-3 · Cited by 501
Mechanism of action of and resistance to quinolones
Fàbrega, A., Madurga, S., Giralt, E., & Vila, J. (2009) · Microbial Biotechnology · doi:10.1111/j.1751-7915.2008.00063.x · Cited by 482
Natural products: A lead for drug discovery and development
Chopra, B., & Dhingra, A. K. (2021) · Phytotherapy Research · doi:10.1002/ptr.7099 · Cited by 469
Fragment-Based Lead Discovery Using X-ray Crystallography
Hartshorn, M. J., Murray, C. W., Cleasby, A., Frederickson, M., Tickle, I. J., & Jhoti, H. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0495778 · Cited by 422
Pellecchia, M., Sem, D. S., & Wüthrich, K. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd748 · Cited by 420
Virtual screening and fast automated docking methods
Schneider, G., & Böhm, H.-J. (2002) · Drug Discovery Today · doi:10.1016/s1359-6446(01)02091-8 · Cited by 404
Surface Plasmon Resonance (SPR) Biosensors in Pharmaceutical Analysis
Olaru, A., Bala, C., Jaffrezic-Renault, N., & Aboul-Enein, H. Y. (2015) · Critical Reviews in Analytical Chemistry · doi:10.1080/10408347.2014.881250 · Cited by 400
Tethering: Fragment-Based Drug Discovery
Erlanson, D. A., Wells, J. A., & Braisted, A. C. (2004) · Annual Review of Biophysics and Biomolecular Structure · doi:10.1146/annurev.biophys.33.110502.140409 · Cited by 385
Virtual Screening Using Protein−Ligand Docking: Avoiding Artificial Enrichment
Verdonk, M. L., Berdini, V., Hartshorn, M. J., Mooij, W. T. M., Murray, C. W., Taylor, R. D., & Watson, P. (2004) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci034289q · Cited by 380
Recent advances in computer-aided drug design
Song, C. M., Lim, S. J., & Tong, J. C. (2009) · Briefings in Bioinformatics · doi:10.1093/bib/bbp023 · Cited by 344
High-throughput docking for lead generation
Abagyan, R., & Totrov, M. (2001) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(00)00217-9 · Cited by 343
Fragment-based lead discovery: leads by design
Carr, R. A. E., Congreve, M., Murray, C. W., & Rees, D. C. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03511-7 · Cited by 343
Keynote review: Structural biology and drug discovery
Congreve, M., Murray, C. W., & Blundell, T. L. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03484-7 · Cited by 338
Theory and Applications of NMR-Based Screening in Pharmaceutical Research
Lepre, C. A., Moore, J. M., & Peng, J. W. (2004) · Chemical Reviews · doi:10.1021/cr030409h · Cited by 322
Cell-division inhibitors: new insights for future antibiotics
Lock, R. L., & Harry, E. J. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2510 · Cited by 263
Hit discovery and hit-to-lead approaches
Keserű, G. M., & Makara, G. M. (2006) · Drug Discovery Today · doi:10.1016/j.drudis.2006.06.016 · Cited by 256
Discovery of a Potent Small Molecule IL-2 Inhibitor through Fragment Assembly
Braisted, A. C., Oslob, J. D., Delano, W. L., Hyde, J., McDowell, R. S., Waal, N., Yu, C., Arkin, M. R., & Raimundo, B. C. (2003) · Journal of the American Chemical Society · doi:10.1021/ja034247i · Cited by 256
Metadata
- Authors
- Boehm, H.-J., Boehringer, M., Bur, D., Gmuender, H., Huber, W., Klaus, W., Kostrewa, D., Kuehne, H., Luebbers, T., Meunier-Keller, N., & Mueller, F.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2000-06-23
- Volume
- 43
- Issue
- 14
- Pages
- 2664-2674
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2014989916
- Cited by
- 375
- References
- 20
- FWCI
- 26.55
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.